Fractyl Health Inc
GUTS2.280USD
+0.080+3.64%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
301.45MMarket Cap
LossP/E TTM
More Details of Fractyl Health Inc Company
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Fractyl Health Inc Info
Ticker SymbolGUTS
Company nameFractyl Health Inc
IPO dateFeb 02, 2024
CEORajagopalan (Harith)
Number of employees107
Security typeOrdinary Share
Fiscal year-endFeb 02
Address3 Van De Graaff Drive
CityBURLINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01803
Phone17819028800
Websitehttps://www.fractyl.com/
Ticker SymbolGUTS
IPO dateFeb 02, 2024
CEORajagopalan (Harith)
Company Executives of Fractyl Health Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jay D. Caplan
Mr. Jay D. Caplan
President, Co-Founder, Chief Product Officer
President, Co-Founder, Chief Product Officer
631.16K
--
Mr. William W. Bradley
Mr. William W. Bradley
Independent Director
Independent Director
16.13K
--
Christopher Thompson
Christopher Thompson
Independent Director
Independent Director
--
--
Mr. Ian D. Sheffield
Mr. Ian D. Sheffield
Independent Director
Independent Director
--
--
Mr. Kelly M. Barnes
Mr. Kelly M. Barnes
Independent Director
Independent Director
--
--
Dr. Timothy Kieffer, Ph.D.
Dr. Timothy Kieffer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Marc Elia
Mr. Marc Elia
Independent Director
Independent Director
--
--
Dr. Clive Meanwell, M.D.
Dr. Clive Meanwell, M.D.
Independent Director
Independent Director
--
--
Ms. Lisa A. Davidson
Ms. Lisa A. Davidson
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Ajay Royan
Mr. Ajay Royan
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jay D. Caplan
Mr. Jay D. Caplan
President, Co-Founder, Chief Product Officer
President, Co-Founder, Chief Product Officer
631.16K
--
Mr. William W. Bradley
Mr. William W. Bradley
Independent Director
Independent Director
16.13K
--
Christopher Thompson
Christopher Thompson
Independent Director
Independent Director
--
--
Mr. Ian D. Sheffield
Mr. Ian D. Sheffield
Independent Director
Independent Director
--
--
Mr. Kelly M. Barnes
Mr. Kelly M. Barnes
Independent Director
Independent Director
--
--
Dr. Timothy Kieffer, Ph.D.
Dr. Timothy Kieffer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.86%
SilverArc Capital Management, LLC
7.73%
Mithril Capital Management LLC
4.68%
Alyeska Investment Group, L.P.
4.12%
Woodline Partners LP
4.02%
Other
70.59%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.86%
SilverArc Capital Management, LLC
7.73%
Mithril Capital Management LLC
4.68%
Alyeska Investment Group, L.P.
4.12%
Woodline Partners LP
4.02%
Other
70.59%
Shareholder Types
Shareholders
Proportion
Hedge Fund
43.24%
Venture Capital
16.41%
Investment Advisor
8.48%
Investment Advisor/Hedge Fund
3.30%
Individual Investor
1.53%
Research Firm
0.44%
Corporation
0.21%
Other
26.39%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
141
38.87M
30.31%
-4.55M
2025Q2
138
42.30M
85.72%
-4.23M
2025Q1
136
42.76M
87.34%
-3.14M
2024Q4
120
43.49M
88.96%
+3.97M
2024Q3
107
43.47M
90.59%
+7.28M
2024Q2
78
41.00M
85.51%
+3.75M
2024Q1
52
42.08M
87.80%
+17.91M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Mithril Capital Management LLC
6.41M
4.86%
+333.33K
+5.48%
Sep 30, 2024
Woodline Partners LP
597.84K
0.45%
+80.92K
+15.65%
Jun 30, 2025
683 Capital Management LLC
645.00K
0.49%
-5.00K
-0.77%
Jun 30, 2025
Catalio Capital Management, LP
214.24K
0.16%
--
--
Jun 30, 2025
General Catalyst Partners
4.88M
3.71%
+7.00
+0.00%
Jun 30, 2025
Bessemer Venture Partners
4.77M
3.62%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Small-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Fractyl Health Inc?
The top five shareholders of Fractyl Health Inc are:
Mithril Capital Management LLC holds 6.41M shares, accounting for 4.86% of the total shares.
Woodline Partners LP holds 597.84K shares, accounting for 0.45% of the total shares.
683 Capital Management LLC holds 645.00K shares, accounting for 0.49% of the total shares.
Catalio Capital Management, LP holds 214.24K shares, accounting for 0.16% of the total shares.
General Catalyst Partners holds 4.88M shares, accounting for 3.71% of the total shares.
Mithril Capital Management LLC holds 6.41M shares, accounting for 4.86% of the total shares.
Woodline Partners LP holds 597.84K shares, accounting for 0.45% of the total shares.
683 Capital Management LLC holds 645.00K shares, accounting for 0.49% of the total shares.
Catalio Capital Management, LP holds 214.24K shares, accounting for 0.16% of the total shares.
General Catalyst Partners holds 4.88M shares, accounting for 3.71% of the total shares.
What are the top three shareholder types of Fractyl Health Inc?
The top three shareholder types of Fractyl Health Inc are:
Nantahala Capital Management, LLC
SilverArc Capital Management, LLC
Mithril Capital Management LLC
Nantahala Capital Management, LLC
SilverArc Capital Management, LLC
Mithril Capital Management LLC
How many institutions hold shares of Fractyl Health Inc (GUTS)?
As of 2025Q3, 141 institutions hold shares of Fractyl Health Inc, with a combined market value of approximately 38.87M, accounting for 30.31% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -55.40%.
What is the biggest source of revenue for Fractyl Health Inc?
In --, the -- business generated the highest revenue for Fractyl Health Inc, amounting to -- and accounting for --% of total revenue.
